ClinicalTrials.gg
CompletedNCT02187055ORAL STRATEGYUpdated Jun 27, 2018Results posted

An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

A Phase 4 interventional study of Tofacitinib with methotrexate and Tofacitinib without methotrexate in Rhematoid Arthritis, sponsored by Pfizer. Completed at 215 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-27.

Sponsored by Pfizer · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,152
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To assess the efficacy of tofacitinib monotherapy or tofacitinib with methotrexate as compared to adalimumab with methotrexate. To compare the efficacy of tofacitinib monotherapy compared to tofacitinib combined with methotrexate. To compare effects on all health outcomes measures in the study. To evaluate the safety and tolerability of tofacitinib and adalimumab. To evaluate the safety of the zoster vaccine given prior to the initiation of tofacitinb or adalimumab.

02

Conditions studied

  • Rhematoid Arthritis
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have moderate to severe rheumatoid arthritis
  • On methotrexate but inadequately controlled
  • Subjects must not have active tuberculosis or an inadequately treated tuberculosis infection
  • Subjects must use

Exclusion criteria

Exclusion Criteria:

  • Subjects who have been previously treated with adalimumab or Tofacitinib
  • Subjects with any current or a history of malignancy, with the exception of adequately treated or excised non basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
  • Subjects with specific laboratory test abnormalities
  • Subjects with specific types of infections
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,152 participants (actual)

Study arms

  • Experimental
    Tofacitinib 5 mg twice daily with methotrexate

    Drug: Tofacitinib with methotrexate

  • Experimental
    Tofacitinib 5 mg twice daily monotherapy

    Drug: Tofacitinib without methotrexate

  • Active comparator
    Adalimumab with methotrexate

    Biological: Adalimumab with methotrexate

Interventions

  • DrugTofacitinib with methotrexate

    Drug pages: Tofacitinib · Methotrexate

    Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months

  • DrugTofacitinib without methotrexate

    Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months

  • BiologicalAdalimumab with methotrexate

    Drug pages: Adalimumab · Methotrexate

    Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology Criteria 50% Improvement (ACR50) Response at Month 6

    ACR50 is a greater than or equal to (≥) 50 percent (%) improvement in tender joint count (TJC) or swollen joint count (SJC) and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment (PGA) of disease activity, 2) participant's assessment (PtGA) of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein (CRP) at each visit.

    Time frame: Month 6

Secondary outcomes

  1. Change From Baseline in Simplified Disease Activity Index (SDAI) Value at Month 6

    SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 centimeter (cm) visual analogue scale (VAS) (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI less than or equal to (≤) 3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity, \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity.

    Time frame: Month 6

  2. Change From Baseline in Clinical Disease Activity Index (CDAI) Value at Month 6

    CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.

    Time frame: Month 6

  3. Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including CRP at Month 6

    DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\* PtGA (millimeters \[mm\]) + 0.96. Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-4 (CRP) ≤3.2 indicates low disease activity, \>3.2 to 5.1 indicates moderate to high disease activity, and less than (\<) 2.6 indicates remission.

    Time frame: Month 6

  4. Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including Erythrocyte Sedimentation Rate (ESR) at Month 6

    DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*ln(ESR) + 0.014\* PtGA (mm). Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-3 (ESR) ≤3.2 indicates low disease activity, \>3.2 to 5.1 indicates moderate to high disease activity, and \<2.6 indicates remission.

    Time frame: Month 6

  5. Percentage of Participants Achieving Observed American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean Remission Criteria at Month 6

    To meet the ACR-EULAR Boolean remission criteria, a participant must satisfy all of the following: TJC ≤1 and SJC ≤1 (both based on a 28-joint assessment), CRP ≤1 mg/dL, and PtGA ≤1 on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity).

    Time frame: Month 6

  6. Percentage of Participants Achieving SDAI ≤3.3 at Month 6

    SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI ≤3.3 indicates disease remission.

    Time frame: Month 6

  7. Percentage of Participants Achieving CDAI ≤2.8 at Month 6

    CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission.

    Time frame: Month 6

  8. Percentage of Participants Achieving DAS28-4 (ESR) <2.6 at Month 6

    DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*ln(ESR) + 0.014\* PtGA (mm). Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (ESR) \<2.6 indicates disease remission.

    Time frame: Month 6

  9. Percentage of Participants Achieving DAS28-4 (CRP) <2.6 at Month 6

    DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\* PtGA (mm) + 0.96. Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (CRP) \<2.6 indicates remission.

    Time frame: Month 6

  10. Percentage of Participants Achieving SDAI ≤11 at Month 6

    SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI ≤3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity.

    Time frame: Month 6

  11. Percentage of Participants Achieving CDAI ≤10 at Month 6

    CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity.

    Time frame: Month 6

  12. Percentage of Participants Achieving DAS28-4 (ESR) ≤3.2 at Month 6

    DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*ln(ESR) + 0.014\* PtGA (mm). Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (ESR) ≤3.2 indicates low disease activity.

    Time frame: Month 6

  13. Percentage of Participants Achieving DAS28-4 (CRP) ≤3.2 at Month 6

    DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\* PtGA + 0.96. Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-4 (CRP) ≤3.2 indicates low disease activity.

    Time frame: Month 6

  14. Percentage of Participants Achieving American College of Rheumatology Criteria 20% Improvement (ACR20) Response at Month 6

    ACR20 response is a ≥20% improvement in TJC or SJC and 20% improvement in 3 of the following 5 criteria: 1) PGA of disease activity, 2) PtGA of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit.

    Time frame: Month 6

  15. Percentage of Participants Achieving American College of Rheumatology Criteria 70% Improvement (ACR70) Response at Month 6

    ACR70 response is a ≥70% improvement in TJC or SJC and 70% improvement in 3 of the following 5 criteria: 1) PGA of disease activity, 2) PtGA of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit.

    Time frame: Month 6

  16. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Month 6

    The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dressing and grooming, arising, eating, walking, reach, grip, hygiene and other activities over the past week. Each activity category consists of 2 to 3 items. Each item is scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Any activity requiring assistance from another individual or the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty.

    Time frame: Month 6

  17. Percentage of Participants Achieving an HAQ-DI Decrease of at Least 0.22 at Month 6

    The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dressing and grooming, arising, eating, walking, reach, grip, hygiene and other activities over the past week. Each activity category consists of 2 to 3 items. Each item is scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Any activity requiring assistance from another individual or the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. A decrease of 0.22 or more is considered a positive response.

    Time frame: Month 6

  18. Change From Baseline in the Short-Form-36 (SF-36) Health Survey, Physical Component Score at Month 6

    The SF-36 health survey is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based scores for both the SF-36 version 2 (v2) and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher PCS score represents better physical health status.

    Time frame: Month 6

  19. Change From Baseline in the SF-36 Health Survey, Mental Component Score at Month 6

    The SF-36 health survey is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The health domains are aggregated into two summary scores known as the PCS score and the MCS score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher MCS score represents better physical health status.

    Time frame: Month 6

  20. Change From Baseline in the SF-36 Health Survey, Physical Functioning Domain Score at Month 6

    SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 10 items of the physical functioning scale represent levels and kinds of limitations between extremes of physical activities, including lifting and carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence and extent of physical limitations using a 3-level response continuum. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher physical functioning domain score represents better physical functioning.

    Time frame: Month 6

  21. Change From Baseline in the SF-36 Health Survey, Role Physical Domain Score at Month 6

    SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 4-item role physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; and d) accomplishing less. Items in the role physical scale are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher role physical domain score represents better role physical functioning.

    Time frame: Month 6

  22. Change From Baseline in the SF-36 Health Survey, Bodily Pain Domain Score at Month 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher bodily pain domain score represents less bodily pain.

    Time frame: Month 6

  23. Change From Baseline in the SF-36 Health Survey, General Health Domain Score at Month 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The general health scale consists of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher general health domain score represents better general health perceptions.

    Time frame: Month 6

  24. Change From Baseline in the SF-36 Health Survey, Vitality Domain Score at Month 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher vitality domain score represents better vitality.

    Time frame: Month 6

  25. Change From Baseline in the SF-36 Health Survey, Social Functioning Domain Score at Month 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 2-item social functioning scale assesses health-related effects on quantity and quality of social activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher social functioning domain score represents better social functioning.

    Time frame: Month 6

  26. Change From Baseline in the SF-36 Health Survey, Role Emotional Domain Score at Month 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 3-item role emotional scale assesses mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. All 3 items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher role emotional domain score represents better role emotional functioning.

    Time frame: Month 6

  27. Change From Baseline in the SF-36 Health Survey, Mental Health Domain Score at Month 6

    The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. All items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher mental health domain score represents better mental health functioning.

    Time frame: Month 6

  28. Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Questionnaire at Month 6

    The WPAI: Rheumatoid Arthritis is a 6 item questionnaire that is specific for rheumatoid arthritis and yields four types of scores: absenteeism, presenteesism (impairment at work/reduced job effectiveness), work productivity loss and activity impairment. WPAI outcomes are expressed as impairment percentages ranging from 0 to 100, with higher numbers indicating greater impairment and less productivity.

    Time frame: Month 6

  29. Change From Baseline in the EuroQol European Quality of Life-5 Dimensions (EuroQol EQ-5D) at Month 6

    The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). This profile of scores across the 5-dimensions (e.g. 11231, 33212, etc.) is transformed into a single health utility score using a formula developed by the EuroQol Group that applies country specific preference weights. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rated the current health state on a scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicating a better health state.

    Time frame: Month 6

  30. Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale Total Score at Month 6

    FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). The larger the participant's response (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).

    Time frame: Month 6

07

Results

Posted Jun 27, 2018

Participant flow

Participant flow — Overall Study
MilestoneTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Started384376386
Completed315303312
Not completed697374
Withdrew: Lack of efficacy1037
Withdrew: Lost to follow-up273
Withdrew: No longer meets eligibility criteria020
Withdrew: No longer willing to participate6810
Withdrew: Other563
Withdrew: Protocol violation994
Withdrew: Pregnancy310
Withdrew: Withdrawal by subject111111
Withdrew: Adverse event212636
Withdrew: Death200

Outcome measures

PrimaryPercentage of Participants Achieving American College of Rheumatology Criteria 50% Improvement (ACR50) Response at Month 6

ACR50 is a greater than or equal to (≥) 50 percent (%) improvement in tender joint count (TJC) or swollen joint count (SJC) and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment (PGA) of disease activity, 2) participant's assessment (PtGA) of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein (CRP) at each visit.

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving American College of Rheumatology Criteria 50% Improvement (ACR50) Response at Month 6
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Percentage of Participants Achieving American College of Rheumatology Criteria 50% Improvement (ACR50) Response at Month 638.2846.0143.78
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Normal approximation to proportions · p = 0.2101 · Difference in response rate: -7.73 · 98.34% CI -16.29 to 0.83Multiplicity-adjusted
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Normal approximation to proportions · p = 0.0512 · Difference in response rate: -5.50 · 98.34% CI -13.98 to 2.98Multiplicity-adjusted
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Normal approximation to proportions · p = <0.0001 · Difference in response rate: 2.23 · 98.34% CI -6.40 to 10.86Multiplicity adjusted
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI) Value at Month 6

SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 centimeter (cm) visual analogue scale (VAS) (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI less than or equal to (≤) 3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity, \>11 to 26 indicates moderate disease activity, and \>26 indicates high disease activity.

Time frame:
Month 6
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI) Value at Month 6
Score on a scaleTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Change From Baseline in Simplified Disease Activity Index (SDAI) Value at Month 6-23.7 ± 0.62-26.6 ± 0.62-25.6 ± 0.62
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: 2.8 · 95% CI 1.23 to 4.41
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 1.9 · 95% CI 0.33 to 3.49
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: -0.9 · 95% CI -2.51 to 0.68
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) Value at Month 6

CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity, \>10 to 22 indicates moderate disease activity, and \>22 indicates high disease activity.

Time frame:
Month 6
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) Value at Month 6
Score on a scaleTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Change From Baseline in Clinical Disease Activity Index (CDAI) Value at Month 6-22.9 ± 0.61-25.5 ± 0.61-24.8 ± 0.61
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: 2.6 · 95% CI 1.08 to 4.18
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 1.9 · 95% CI 0.40 to 3.48
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: -0.7 · 95% CI -2.24 to 0.86
SecondaryChange From Baseline in Disease Activity Score 28-4 (DAS28-4) Including CRP at Month 6

DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\* PtGA (millimeters \[mm\]) + 0.96. Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-4 (CRP) ≤3.2 indicates low disease activity, \>3.2 to 5.1 indicates moderate to high disease activity, and less than (\<) 2.6 indicates remission.

Time frame:
Month 6
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including CRP at Month 6
Score on a scaleTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including CRP at Month 6-2.1 ± 0.07-2.5 ± 0.07-2.3 ± 0.07
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: 0.3 · 95% CI 0.16 to 0.50
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 0.2 · 95% CI 0.05 to 0.39
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: -0.1 · 95% CI -0.28 to 0.06
SecondaryChange From Baseline in Disease Activity Score 28-4 (DAS28-4) Including Erythrocyte Sedimentation Rate (ESR) at Month 6

DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*ln(ESR) + 0.014\* PtGA (mm). Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-3 (ESR) ≤3.2 indicates low disease activity, \>3.2 to 5.1 indicates moderate to high disease activity, and \<2.6 indicates remission.

Time frame:
Month 6
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including Erythrocyte Sedimentation Rate (ESR) at Month 6
Score on a scaleTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including Erythrocyte Sedimentation Rate (ESR) at Month 6-2.1 ± 0.07-2.4 ± 0.07-2.4 ± 0.07
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: 0.3 · 95% CI 0.15 to 0.51
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 0.3 · 95% CI 0.10 to 0.46
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: -0.0 · 95% CI -0.23 to 0.13
SecondaryPercentage of Participants Achieving Observed American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean Remission Criteria at Month 6

To meet the ACR-EULAR Boolean remission criteria, a participant must satisfy all of the following: TJC ≤1 and SJC ≤1 (both based on a 28-joint assessment), CRP ≤1 mg/dL, and PtGA ≤1 on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity).

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Observed American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean Remission Criteria at Month 6
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Percentage of Participants Achieving Observed American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean Remission Criteria at Month 67.548.679.58
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Difference in remission rate: -1.21 · 95% CI -4.99 to 2.56
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Difference in remission rate: -1.78 · 95% CI -5.59 to 2.04
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Difference in remission rate: -0.56 · 95% CI -4.53 to 3.40
SecondaryPercentage of Participants Achieving SDAI ≤3.3 at Month 6

SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI ≤3.3 indicates disease remission.

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving SDAI ≤3.3 at Month 6
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Percentage of Participants Achieving SDAI ≤3.3 at Month 610.64 ± 0.6213.91 ± 0.6214.37 ± 0.62
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Difference in remission rate: -3.40 · 95% CI -7.95 to 1.15
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Difference in remission rate: -3.06 · 95% CI -7.55 to 1.43
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Difference in remission rate: 0.34 · 95% CI -4.45 to 5.14
SecondaryPercentage of Participants Achieving CDAI ≤2.8 at Month 6

CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission.

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving CDAI ≤2.8 at Month 6
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Percentage of Participants Achieving CDAI ≤2.8 at Month 610.8914.7014.57
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Difference in remission rate: -3.67 · 95% CI -8.29 to 0.94
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Difference in remission rate: -3.06 · 95% CI -7.59 to 1.48
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Difference in remission rate: 0.62 · 95% CI -4.24 to 5.47
SecondaryPercentage of Participants Achieving DAS28-4 (ESR) <2.6 at Month 6

DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*ln(ESR) + 0.014\* PtGA (mm). Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (ESR) \<2.6 indicates disease remission.

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving DAS28-4 (ESR) <2.6 at Month 6
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Percentage of Participants Achieving DAS28-4 (ESR) <2.6 at Month 611.3312.7913.58
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Difference in remission rate: -1.55 · 95% CI -6.03 to 2.93
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Difference in remission rate: -2.02 · 95% CI -6.51 to 2.47
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Difference in remission rate: -0.47 · 95% CI -5.11 to 4.18
SecondaryPercentage of Participants Achieving DAS28-4 (CRP) <2.6 at Month 6

DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\* PtGA (mm) + 0.96. Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (CRP) \<2.6 indicates remission.

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving DAS28-4 (CRP) <2.6 at Month 6
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Percentage of Participants Achieving DAS28-4 (CRP) <2.6 at Month 622.6932.7530.17
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Difference in remission rate: -9.49 · 95% CI -15.68 to -3.30
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Difference in remission rate: -6.89 · 95% CI -12.94 to -0.83
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Difference in remission rate: 2.61 · 95% CI -3.86 to 9.07
SecondaryPercentage of Participants Achieving SDAI ≤11 at Month 6

SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI ≤3.3 indicates disease remission, \>3.4 to 11 indicates low disease activity.

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving SDAI ≤11 at Month 6
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Percentage of Participants Achieving SDAI ≤11 at Month 646.78 ± 0.6253.33 ± 0.6251.15 ± 0.62
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Difference in response rate: -6.24 · 95% CI -13.32 to 0.84
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Difference in response rate: -3.66 · 95% CI -10.69 to 3.37
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Difference in response rate: 2.58 · 95% CI -4.51 to 9.68
SecondaryPercentage of Participants Achieving CDAI ≤10 at Month 6

CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission, \>2.8 to 10 indicates low disease activity.

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving CDAI ≤10 at Month 6
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Percentage of Participants Achieving CDAI ≤10 at Month 645.5352.4550.00
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Difference in response rate: -6.22 · 95% CI -13.29 to 0.85
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Difference in response rate: -3.93 · 95% CI -10.94 to 3.09
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Difference in response rate: 2.30 · 95% CI -4.79 to 9.39
SecondaryPercentage of Participants Achieving DAS28-4 (ESR) ≤3.2 at Month 6

DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.70\*ln(ESR) + 0.014\* PtGA (mm). Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (ESR) ≤3.2 indicates low disease activity.

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving DAS28-4 (ESR) ≤3.2 at Month 6
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Percentage of Participants Achieving DAS28-4 (ESR) ≤3.2 at Month 622.1028.4929.77
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Difference in response rate: -6.02 · 95% CI -12.05 to 0.00
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Difference in response rate: -6.89 · 95% CI -12.90 to -0.87
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Difference in response rate: -0.87 · 95% CI -7.17 to 5.44
SecondaryPercentage of Participants Achieving DAS28-4 (CRP) ≤3.2 at Month 6

DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\* PtGA + 0.96. Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-4 (CRP) ≤3.2 indicates low disease activity.

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving DAS28-4 (CRP) ≤3.2 at Month 6
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Percentage of Participants Achieving DAS28-4 (CRP) ≤3.2 at Month 644.5449.5750.86
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Difference in response rate: -4.87 · 95% CI -11.92 to 2.18
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Difference in response rate: -5.48 · 95% CI -12.49 to 1.52
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Difference in rresponse rate: -0.61 · 95% CI -7.70 to 6.47
SecondaryPercentage of Participants Achieving American College of Rheumatology Criteria 20% Improvement (ACR20) Response at Month 6

ACR20 response is a ≥20% improvement in TJC or SJC and 20% improvement in 3 of the following 5 criteria: 1) PGA of disease activity, 2) PtGA of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit.

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving American College of Rheumatology Criteria 20% Improvement (ACR20) Response at Month 6
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Percentage of Participants Achieving American College of Rheumatology Criteria 20% Improvement (ACR20) Response at Month 670.0679.1377.65
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Difference in response rate: -8.29 · 95% CI -14.84 to -1.75
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Difference in response rate: -6.14 · 95% CI -12.72 to 0.44
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Difference in response rate: 2.15 · 95% CI -4.22 to 8.52
SecondaryPercentage of Participants Achieving American College of Rheumatology Criteria 70% Improvement (ACR70) Response at Month 6

ACR70 response is a ≥70% improvement in TJC or SJC and 70% improvement in 3 of the following 5 criteria: 1) PGA of disease activity, 2) PtGA of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit.

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving American College of Rheumatology Criteria 70% Improvement (ACR70) Response at Month 6
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Percentage of Participants Achieving American College of Rheumatology Criteria 70% Improvement (ACR70) Response at Month 619.6627.1122.64
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Difference in response rate: -6.77 · 95% CI -12.61 to -0.93
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Difference in response rate: -2.50 · 95% CI -8.09 to 3.10
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Difference in response rate: 4.27 · 95% CI -1.68 to 10.23
SecondaryChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Month 6

The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dressing and grooming, arising, eating, walking, reach, grip, hygiene and other activities over the past week. Each activity category consists of 2 to 3 items. Each item is scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Any activity requiring assistance from another individual or the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty.

Time frame:
Month 6
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Month 6
Units on a scaleTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Month 6-0.52 ± 0.031-0.58 ± 0.031-0.54 ± 0.031
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: 0.07 · 95% CI -0.011 to 0.148
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 0.03 · 95% CI -0.054 to 0.105
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: -0.04 · 95% CI -0.122 to 0.037
SecondaryPercentage of Participants Achieving an HAQ-DI Decrease of at Least 0.22 at Month 6

The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dressing and grooming, arising, eating, walking, reach, grip, hygiene and other activities over the past week. Each activity category consists of 2 to 3 items. Each item is scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Any activity requiring assistance from another individual or the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. A decrease of 0.22 or more is considered a positive response.

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an HAQ-DI Decrease of at Least 0.22 at Month 6
Percentage of participantsTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Percentage of Participants Achieving an HAQ-DI Decrease of at Least 0.22 at Month 671.0775.5772.86
Statistical analysis
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Difference in response rate: -4.07 · 95% CI -10.68 to 2.55
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Difference in response rate: -1.21 · 95% CI -7.87 to 5.44
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Difference in response rate: 2.86 · 95% CI -3.72 to 9.43
SecondaryChange From Baseline in the Short-Form-36 (SF-36) Health Survey, Physical Component Score at Month 6

The SF-36 health survey is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based scores for both the SF-36 version 2 (v2) and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher PCS score represents better physical health status.

Time frame:
Month 6
Reported as:
Least squares mean · Score on a scale
Change From Baseline in the Short-Form-36 (SF-36) Health Survey, Physical Component Score at Month 6
Score on a scaleTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Change From Baseline in the Short-Form-36 (SF-36) Health Survey, Physical Component Score at Month 66.7 ± 0.447.9 ± 0.437.8 ± 0.43
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: -1.2 · 95% CI -2.28 to -0.11
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: -1.1 · 95% CI -2.16 to 0.01
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: 0.1 · 95% CI -0.97 to 1.20
SecondaryChange From Baseline in the SF-36 Health Survey, Mental Component Score at Month 6

The SF-36 health survey is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The health domains are aggregated into two summary scores known as the PCS score and the MCS score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher MCS score represents better physical health status.

Time frame:
Month 6
Reported as:
Least squares mean · Score on a scale
Change From Baseline in the SF-36 Health Survey, Mental Component Score at Month 6
Score on a scaleTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Change From Baseline in the SF-36 Health Survey, Mental Component Score at Month 65.2 ± 0.525.7 ± 0.514.4 ± 0.51
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: -0.4 · 95% CI -1.74 to 0.85
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 0.8 · 95% CI -0.48 to 2.11
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: 1.3 · 95% CI -0.04 to 2.56
SecondaryChange From Baseline in the SF-36 Health Survey, Physical Functioning Domain Score at Month 6

SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 10 items of the physical functioning scale represent levels and kinds of limitations between extremes of physical activities, including lifting and carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence and extent of physical limitations using a 3-level response continuum. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher physical functioning domain score represents better physical functioning.

Time frame:
Month 6
Reported as:
Least squares mean · Score on a scale
Change From Baseline in the SF-36 Health Survey, Physical Functioning Domain Score at Month 6
Score on a scaleTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Change From Baseline in the SF-36 Health Survey, Physical Functioning Domain Score at Month 66.4 ± 0.527.3 ± 0.527.3 ± 0.52
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: -0.9 · 95% CI -2.22 to 0.39
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: -0.9 · 95% CI -2.19 to 0.42
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: 0.0 · 95% CI -1.27 to 1.34
SecondaryChange From Baseline in the SF-36 Health Survey, Role Physical Domain Score at Month 6

SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 4-item role physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; and d) accomplishing less. Items in the role physical scale are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher role physical domain score represents better role physical functioning.

Time frame:
Month 6
Reported as:
Least squares mean · Score on a scale
Change From Baseline in the SF-36 Health Survey, Role Physical Domain Score at Month 6
Score on a scaleTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Change From Baseline in the SF-36 Health Survey, Role Physical Domain Score at Month 66.7 ± 0.477.0 ± 0.476.3 ± 0.47
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: -0.3 · 95% CI -1.52 to 0.87
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 0.4 · 95% CI -0.80 to 1.58
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: 0.7 · 95% CI -0.47 to 1.91
SecondaryChange From Baseline in the SF-36 Health Survey, Bodily Pain Domain Score at Month 6

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher bodily pain domain score represents less bodily pain.

Time frame:
Month 6
Reported as:
Least squares mean · Score on a scale
Change From Baseline in the SF-36 Health Survey, Bodily Pain Domain Score at Month 6
Score on a scaleTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Change From Baseline in the SF-36 Health Survey, Bodily Pain Domain Score at Month 68.2 ± 0.4810.3 ± 0.489.9 ± 0.48
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: -2.0 · 95% CI -3.25 to -0.80
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: -1.7 · 95% CI -2.91 to -0.47
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: 0.3 · 95% CI -0.89 to 1.55
SecondaryChange From Baseline in the SF-36 Health Survey, General Health Domain Score at Month 6

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The general health scale consists of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher general health domain score represents better general health perceptions.

Time frame:
Month 6
Reported as:
Least squares mean · Score on a scale
Change From Baseline in the SF-36 Health Survey, General Health Domain Score at Month 6
Score on a scaleTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Change From Baseline in the SF-36 Health Survey, General Health Domain Score at Month 65.1 ± 0.446.3 ± 0.445.4 ± 0.44
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: -1.2 · 95% CI -2.27 to -0.05
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: -0.3 · 95% CI -1.40 to 0.82
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: 0.9 · 95% CI -0.25 to 1.98
SecondaryChange From Baseline in the SF-36 Health Survey, Vitality Domain Score at Month 6

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher vitality domain score represents better vitality.

Time frame:
Month 6
Reported as:
Least squares mean · Score on a scale
Change From Baseline in the SF-36 Health Survey, Vitality Domain Score at Month 6
Score on a scaleTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Change From Baseline in the SF-36 Health Survey, Vitality Domain Score at Month 65.6 ± 0.486.1 ± 0.475.7 ± 0.47
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: -0.5 · 95% CI -1.71 to 0.68
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: -0.1 · 95% CI -1.33 to 1.05
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: 0.4 · 95% CI -0.83 to 1.57
SecondaryChange From Baseline in the SF-36 Health Survey, Social Functioning Domain Score at Month 6

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 2-item social functioning scale assesses health-related effects on quantity and quality of social activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher social functioning domain score represents better social functioning.

Time frame:
Month 6
Reported as:
Least squares mean · Score on a scale
Change From Baseline in the SF-36 Health Survey, Social Functioning Domain Score at Month 6
Score on a scaleTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Change From Baseline in the SF-36 Health Survey, Social Functioning Domain Score at Month 66.3 ± 0.527.2 ± 0.526.2 ± 0.52
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: -0.9 · 95% CI -2.20 to 0.45
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 0.2 · 95% CI -1.13 to 1.51
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: 1.1 · 95% CI -0.26 to 2.39
SecondaryChange From Baseline in the SF-36 Health Survey, Role Emotional Domain Score at Month 6

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 3-item role emotional scale assesses mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. All 3 items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher role emotional domain score represents better role emotional functioning.

Time frame:
Month 6
Reported as:
Least squares mean · Score on a scale
Change From Baseline in the SF-36 Health Survey, Role Emotional Domain Score at Month 6
Score on a scaleTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Change From Baseline in the SF-36 Health Survey, Role Emotional Domain Score at Month 66.7 ± 0.587.7 ± 0.586.0 ± 0.58
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: -1.1 · 95% CI -2.54 to 0.39
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 0.7 · 95% CI -0.76 to 2.16
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: 1.8 · 95% CI 0.30 to 3.24
SecondaryChange From Baseline in the SF-36 Health Survey, Mental Health Domain Score at Month 6

The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. All items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher mental health domain score represents better mental health functioning.

Time frame:
Month 6
Reported as:
Least squares mean · Score on a scale
Change From Baseline in the SF-36 Health Survey, Mental Health Domain Score at Month 6
Score on a scaleTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Change From Baseline in the SF-36 Health Survey, Mental Health Domain Score at Month 65.3 ± 0.525.5 ± 0.525.0 ± 0.52
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: -0.2 · 95% CI -1.55 to 1.08
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 0.3 · 95% CI -1.01 to 1.62
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: 0.5 · 95% CI -0.78 to 1.86
SecondaryChange From Baseline in the Work Productivity and Activity Impairment (WPAI) Questionnaire at Month 6

The WPAI: Rheumatoid Arthritis is a 6 item questionnaire that is specific for rheumatoid arthritis and yields four types of scores: absenteeism, presenteesism (impairment at work/reduced job effectiveness), work productivity loss and activity impairment. WPAI outcomes are expressed as impairment percentages ranging from 0 to 100, with higher numbers indicating greater impairment and less productivity.

Time frame:
Month 6
Reported as:
Least squares mean · Percentage of impairment
Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Questionnaire at Month 6
Percentage of impairmentTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Work hours missed due to problems-2.62 ± 0.717-2.19 ± 0.700-1.75 ± 0.741
Work hours missed other reason0.14 ± 1.0190.43 ± 0.991-0.77 ± 1.059
Hours worked in past 7 days4.13 ± 1.729-0.82 ± 1.6721.28 ± 1.788
Problems affecting productivity-1.94 ± 0.228-2.14 ± 0.224-1.95 ± 0.232
Problem affecting daily activities-2.24 ± 0.137-2.47 ± 0.138-2.24 ± 0.139
% work time missed due to health-4.51 ± 1.790-3.41 ± 1.794-1.87 ± 1.831
% impairment while working due to health-19.38 ± 2.276-21.44 ± 2.235-19.52 ± 2.320
% overall work impairment due to health-20.16 ± 2.663-22.27 ± 2.638-21.87 ± 2.710
% activity impairment due to health-22.36 ± 1.375-24.74 ± 1.383-22.45 ± 1.394
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: -0.43 · 95% CI -2.279 to 1.427
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: -0.87 · 95% CI -2.783 to 1.044
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: -0.44 · 95% CI -2.349 to 1.462
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: -0.29 · 95% CI -2.928 to 2.346
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 0.90 · 95% CI -1.832 to 3.640
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: 1.20 · 95% CI -1.520 to 3.911
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: 4.95 · 95% CI 0.520 to 9.370
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 2.85 · 90% CI -1.736 to 7.430
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: -2.10 · 95% CI -6.650 to 2.454
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: 0.21 · 95% CI -0.373 to 0.786
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 0.01 · 95% CI -0.578 to 0.607
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: -0.19 · 95% CI -0.784 to 0.400
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: 0.24 · 95% CI -0.112 to 0.587
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 0.01 · 95% CI -0.341 to 0.357
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: -0.23 · 95% CI -0.582 to 0.122
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: -1.10 · 95% CI -5.748 to 3.553
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: -2.64 · 95% CI -7.339 to 2.067
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: -1.54 · 95% CI -6.283 to 3.207
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: 2.07 · 95% CI -3.726 to 7.858
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 0.15 · 95% CI -5.777 to 6.068
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: -1.92 · 95% CI -7.839 to 3.998
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: 2.11 · 95% CI -4.664 to 8.877
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 1.71 · 95% CI -5.164 to 8.580
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: -0.40 · 95% CI -7.307 to 6.510
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: 2.38 · 95% CI -1.118 to 5.873
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 0.08 · 95% CI -3.411 to 3.573
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: -2.30 · 95% CI -5.818 to 1.225
SecondaryChange From Baseline in the EuroQol European Quality of Life-5 Dimensions (EuroQol EQ-5D) at Month 6

The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). This profile of scores across the 5-dimensions (e.g. 11231, 33212, etc.) is transformed into a single health utility score using a formula developed by the EuroQol Group that applies country specific preference weights. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rated the current health state on a scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicating a better health state.

Time frame:
Month 6
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the EuroQol European Quality of Life-5 Dimensions (EuroQol EQ-5D) at Month 6
Units on a scaleTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Utility score0.20 ± 0.0130.22 ± 0.0130.22 ± 0.013
Mobility score-0.29 ± 0.027-0.26 ± 0.027-0.28 ± 0.027
Self-care score-0.27 ± 0.028-0.33 ± 0.028-0.32 ± 0.028
Usual activities score-0.24 ± 0.029-0.26 ± 0.029-0.30 ± 0.029
Pain/discomfort score-0.32 ± 0.026-0.34 ± 0.026-0.37 ± 0.026
Anxiety/depression score-0.21 ± 0.029-0.24 ± 0.029-0.22 ± 0.029
VAS score20.84 ± 1.10020.98 ± 1.10019.61 ± 1.100
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: -0.02 · 95% CI -0.057 to 0.011
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: -0.02 · 95% CI -0.054 to 0.013
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: 0.00 · 95% CI -0.031 to 0.036
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: -0.03 · 95% CI -0.098 to 0.042
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: -0.01 · 95% CI -0.079 to 0.060
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: 0.02 · 95% CI -0.051 to 0.089
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: 0.06 · 95% CI -0.014 to 0.127
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 0.04 · 95% CI -0.027 to 0.114
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: -0.01 · 95% CI -0.083 to 0.058
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: 0.01 · 95% CI -0.062 to 0.084
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 0.06 · 95% CI -0.018 to 0.129
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: 0.04 · 95% CI -0.029 to 0.118
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: 0.03 · 95% CI -0.041 to 0.091
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 0.05 · 95% CI -0.015 to 0.116
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: 0.03 · 95% CI -0.041 to 0.091
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: 0.03 · 95% CI -0.046 to 0.103
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 0.01 · 95% CI -0.066 to 0.083
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: -0.02 · 95% CI -0.094 to 0.055
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: -0.14 · 95% CI -2.934 to 2.648
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 1.23 · 95% CI -1.556 to 4.016
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: 1.37 · 95% CI -1.425 to 4.171
SecondaryChange From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale Total Score at Month 6

FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). The larger the participant's response (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).

Time frame:
Month 6
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale Total Score at Month 6
Units on a scaleTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale Total Score at Month 67.14 ± 0.5007.59 ± 0.4986.07 ± 0.499
Statistical analysis
  • Tofacitinib 5 mg BID vs Tofacitinib 5 mg BID + MTX · Ls mean difference: -0.45 · 95% CI -1.706 to 0.808
  • Tofacitinib 5 mg BID vs Adalimumab 40 mg + MTX · Ls mean difference: 1.07 · 95% CI -0.178 to 2.325
  • Tofacitinib 5 mg BID + MTX vs Adalimumab 40 mg + MTX · Ls mean difference: 1.52 · 95% CI 0.266 to 2.779

Adverse events

Collected over SAEs were assessed from informed consent up to at least 28 calendar days after last dose of investigational product. AEs were recorded from the time the subject has taken at least one dose of study treatment through last subject visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib 5 mg BID—35/384 (9.1%)51/384 (13.3%)
Tofacitinib 5 mg BID + MTX—27/376 (7.2%)72/376 (19.1%)
Adalimumab 40 mg + MTX—24/386 (6.2%)69/386 (17.9%)
Most frequent serious events
Showing 10 of 99
Most frequent serious events
EventTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Hip fractureInjury, poisoning and procedural complications0/3843/3760/386
CellulitisInfections and infestations3/3841/3760/386
PyelonephritisInfections and infestations0/3842/3760/386
Chest painGeneral disorders2/3841/3761/386
CholelithiasisHepatobiliary disorders2/3840/3761/386
PyrexiaGeneral disorders0/3840/3762/386
Renal colicRenal and urinary disorders0/3840/3762/386
PancytopeniaBlood and lymphatic system disorders0/3841/3760/386
Myocardial ischaemiaCardiac disorders0/3841/3760/386
Necrotising retinitisEye disorders0/3841/3760/386
Most frequent other events
Most frequent other events
EventTofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTX
Upper respiratory tract infectionInfections and infestations25/38437/37629/386
Alanine aminotransferase increasedInvestigations8/38423/37626/386
NasopharyngitisInfections and infestations22/38416/37618/386

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Tofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTXTotal
Mean49.7 ± 12.250.0 ± 13.450.7 ± 13.450.1 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib 5 mg BIDTofacitinib 5 mg BID + MTXAdalimumab 40 mg + MTXTotal
Female319311320950
Male656566196
08

Study locations

215 sites
  • Rheumatology Associates of North Alabama, PC
    Huntsville, Alabama 35801, United States
  • Arthrocare, Arthritis Care & Research, PC
    Gilbert, Arizona 85234, United States
  • Medvin Clinical Research
    Covina, California 91722, United States
  • St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare
    Fullerton, California 92835, United States
  • HealthCare Partners Medical Group
    Huntington Beach, California 92646, United States
  • Keck Medicine of USC - Division of Rheumatology
    Los Angeles, California 90033, United States
  • University of Southern California (USC) Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
  • Ronald Reagan UCLA Medical Center - Drug Information Center
    Los Angeles, California 90095, United States
  • UCLA David Geffen School of Medicine, Division of Rheumatology
    Los Angeles, California 90095, United States
  • Medvin Clinical Research
    Placentia, California 92870, United States
  • San Diego Arthritis Medical Clinic
    San Diego, California 92108, United States
  • Inland Rheumatology Clinical Trials, Inc.
    Upland, California 91786, United States
  • Medvin Clinical Research
    Van Nuys, California 91405, United States
  • Medvin Clinical Research
    Whittier, California 90602, United States
  • Joao M. A. Nascimento
    Bridgeport, Connecticut 06606, United States
  • AARDS Research, Inc.
    Aventura, Florida 33180, United States
  • Arthritis and Rheumatic Disease Specialties
    Aventura, Florida 33180, United States
  • Riverside Clinical Research
    Edgewater, Florida 32132, United States
  • Centre for Rheumatology, Immunology and Arthritis
    Fort Lauderdale, Florida 33309, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Omega Research Consultants, LLC
    Orlando, Florida 32804, United States
  • Arthritis Center, Inc.
    Palm Harbor, Florida 34684, United States
  • Gulf Region Clinical Research Institute Llc
    Pensacola, Florida 32514, United States
  • West Broward Rheumatology Associates, Inc.
    Tamarac, Florida 33321, United States
  • BayCare Medical Group Inc
    Tampa, Florida 33614, United States
  • The Center for Arthritis and Rheumatism
    Vero Beach, Florida 32960, United States
  • The Office of Alastair C. Kennedy, MD
    Vero Beach, Florida 32960, United States
  • Advanced Clinical Research of Orlando, Inc.
    Winter Garden, Florida 34787, United States
  • Coeur D'Alene Arthritis Clinic
    Coeur d'Alene, Idaho 83814, United States
  • Institute of Arthritis Research
    Idaho Falls, Idaho 83404, United States
  • Deerbrook Medical Associates
    Vernon Hills, Illinois 60061, United States
  • Diagnostic Rheumatology and Research PC
    Indianapolis, Indiana 46227, United States
  • Ochsner Clinic Baton Rouge
    Baton Rouge, Louisiana 70809, United States
  • Arthritis and Diabetes Clinic, Inc
    Monroe, Louisiana 71203, United States
  • Arthritis Treatment Center
    Frederick, Maryland 21702, United States
  • Jasper Clinic
    Kalamazoo, Michigan 49007, United States
  • Arthritis and Osteoporosis Treatment and Research Center
    Flowood, Mississippi 39232, United States
  • St. Louis Center For Clinical Research Barbara Caciolo, MD
    Saint Louis, Missouri 63128, United States
  • Clinvest/ A Division of Banyan Group, Inc.
    Springfield, Missouri 65807, United States
  • Dr. Prem C. Chatpar M.D.,LLC
    Plainview, New York 11803, United States
  • PMG Research of Salisbury, LLC
    Salisbury, North Carolina 28144, United States
  • Rowan Diagnostic Clinic
    Salisbury, North Carolina 28144, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • Trinity Health Center - Medical Arts
    Minot, North Dakota 58701, United States
  • Lynn Health Science Institute
    Oklahoma City, Oklahoma 73112, United States
  • Altoona Center For Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Arthritis Group
    Philadelphia, Pennsylvania 19152-3303, United States
  • Low Country Rheumatology, PA
    Charleston, South Carolina 29406, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Accurate Clinical Management, LLC
    Baytown, Texas 77521, United States
  • Arthritis Care And Diagnostic Center, P.A.
    Dallas, Texas 75231, United States
  • Metroplex Clinical Research Center
    Dallas, Texas 75231, United States
  • Accurate Clinical Management, LLC
    Houston, Texas 77004, United States
  • Rheumatology Clinic of Houston, PA
    Houston, Texas 77065, United States
  • Houston Institute For Clinical Research
    Houston, Texas 77074, United States
  • Arthritis & Osteoporosis Associates, LLP
    Lubbock, Texas 79424, United States
  • Southwest Rheumatology Research, LLC.
    Mesquite, Texas 75150, United States
  • Accurate Clinical Research, Inc.
    San Antonio, Texas 78229, United States
  • Arthritis & Osteoporosis Center of South Texas
    San Antonio, Texas 78232, United States
  • Arthritis Northwest, PLLC
    Spokane, Washington 99204, United States
  • Atencion Integral en Reumatologia (AIR)
    Caba, Buenos Aires C1426AAL, Argentina
  • Centro Medico Privado de Reumatologia
    San Miguel de Tucuman, Tucuman 4000, Argentina
  • Centro Radiologico Luis Mendez Collado SRL
    San Miguel de Tucuman, Tucuman 4000, Argentina
  • Organizacion Medica de Investigacion S.A - OMI
    Buenos Aires, 1015, Argentina
  • CER San Juan, Centro Polivalente de Asistencia e Investigacion Clinica
    San Juan, 5400, Argentina
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Pacific Private Clinic
    Southport, Queensland 4215, Australia
  • QML Pathology
    Southport, Queensland 4215, Australia
  • The Queen Elizabeth Hospital
    Woodville South, South Australia 5011, Australia
  • Emeritus Research
    Malvern East, Victoria 3145, Australia
  • RK Will Pty Ltd
    Victoria Park, Western Australia 6100, Australia
  • University Hospital Clinical Center Banja Luka
    Banja Luka, Republika Srpska 78000, Bosnia and Herzegovina
  • University Clinical Center Tuzla
    Tuzla, 75000, Bosnia and Herzegovina
  • UMHAT "Dr. Georgi Stranski" EAD
    Pleven, 5800, Bulgaria
  • MHAT "Kaspela" EOOD
    Plovdiv, 4002, Bulgaria
  • MHAT EUROHOSPITAL Plovdiv
    Plovdiv, 4004, Bulgaria
  • MHAT Akta Medika OOD
    Ruse, 5400, Bulgaria
  • MHAT Ruse AD
    Ruse, 7002, Bulgaria
  • MHAT Shumen AD
    Shumen, 9700, Bulgaria
  • NMTH Tsar Boris Clinic of Internal Diseases
    Sofia, 1233, Bulgaria
  • MHAT Lyulin EAD
    Sofia, 1336, Bulgaria
  • MHAT "Targovishte" AD
    Targovisthe, 7700, Bulgaria
  • Kw Musculoskeletal Research Inc
    Kitchener, Ontario N2M 5N6, Canada
  • Centre de Recherche Musculo-Squelettique
    Trois-Rivieres, Quebec G8Z 1Y2, Canada
  • Prosalud
    Santiago, Metropolitana 7510047, Chile
  • Estudios Clinicos Quinta Region Ltda.
    Vina del Mar, Valparaiso 2520997, Chile
  • Quantum Research Ltda
    Puerto Varas, X Region 5550170, Chile
  • Quantum Research
    Puerto Varas, X Region 5550170, Chile
  • Revmacentrum MUDr. Mostera, s.r.o.
    Brno - Zidenice, Czech Republic 615 00, Czechia
  • Revmatologie s.r.o.
    Brno, 63800, Czechia
  • Revmatologicka ambulance
    Ceska Lipa, 470 01, Czechia
  • Vesalion, s.r.o.
    Ostrava- Moravska Ostrava, 702 00, Czechia
  • Revmatologie
    Praha 4, 140 00, Czechia
  • Foundation Parnu Hospital
    Parnu, 80010, Estonia
  • East-Tallinn Central Hospital Ltd
    Tallinn, 11312, Estonia
  • North Estonia Medical Centre Foundation
    Tallinn, 13419, Estonia
  • Bnai Zion Medical Center
    Haifa, 31048, Israel
  • Rambam Health Care Campus
    Haifa, 3109601, Israel
  • Hadassah Medical Center
    Jerusalem, 91120, Israel
  • The Chaim Sheba Medical Center
    Tel-Hashomer, 5262000, Israel

Showing the first 100 of 215 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Bessette L, Mysler E, Kinch CD, Kwok K, Lukic T, On PV, van Vollenhoven RF. Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials. J Rheumatol. 2022 Jun;49(6):566-576. doi: 10.3899/jrheum.210707. Epub 2022 Mar 1. PubMed 35232809 ↗
  • Dikranian A, Gold D, Bessette L, Nash P, Azevedo VF, Wang L, Woolcott J, Shapiro AB, Szumski A, Fleishaker D, Wollenhaupt J. Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib. Rheumatol Ther. 2022 Apr;9(2):411-433. doi: 10.1007/s40744-021-00405-w. Epub 2021 Dec 17. PubMed 34921355 ↗
  • Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6. PubMed 34870800 ↗
  • Takeuchi T, Fleischmann R, Iikuni N, Shi H, Soma K, Paulissen J, Hirose T, Smolen JS. Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy. Arthritis Res Ther. 2021 Aug 24;23(1):220. doi: 10.1186/s13075-021-02591-y. PubMed 34429160 ↗
  • Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395. PubMed 33127856 ↗
  • Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20. Erratum In: Dig Dis Sci. 2021 Sep;66(9):3214-3215. doi: 10.1007/s10620-020-06638-z. PubMed 32816215 ↗
  • Strand V, Mysler E, Moots RJ, Wallenstein GV, DeMasi R, Gruben D, Soma K, Iikuni N, Smolen JS, Fleischmann R. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. RMD Open. 2019 Oct 1;5(2):e001040. doi: 10.1136/rmdopen-2019-001040. eCollection 2019. PubMed 31673419 ↗
  • Calabrese LH, Abud-Mendoza C, Lindsey SM, Lee SH, Tatulych S, Takiya L, Iikuni N, Soma K, Luo Z, Fleischmann R. Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study. Arthritis Care Res (Hoboken). 2020 Mar;72(3):353-359. doi: 10.1002/acr.24010. PubMed 31207152 ↗
  • Fleischmann R, Mysler E, Hall S, Kivitz AJ, Moots RJ, Luo Z, DeMasi R, Soma K, Zhang R, Takiya L, Tatulych S, Mojcik C, Krishnaswami S, Menon S, Smolen JS; ORAL Strategy investigators. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16. PubMed 28629665 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2014 to primary completion in Dec 2016, 28 months.

Results were first posted in Jun 2018, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2014
First posted
Jul 10, 2014
StartActual
Aug 2014
Primary completionActual
Dec 2016
CompletionActual
Dec 2016
Results first posted
Jun 27, 2018
Last update
Jun 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02187055
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jul 10, 2014
Start date
Aug 2014
Primary completion
Dec 2016
Completion
Dec 2016
Results posted
Jun 27, 2018
Last update
Jun 27, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tofacitinib · Methotrexate

Start the discussion